DrugsControl Media Services

News Detail

SEC recommends to waive off Phase IV study on Tocilizumab Injection for GCA (20-01-2023)

New Delhi, 20 Jan 2023: The expert committee, that recommends the nation’s drug regulator on approval of new drugs and clinical trials among others, has recommended to waive off the condition for conduct of Phase IV study on Tocilizumab Injection, indicated for Giant Cell A......
View Details

Source : Pharmabiz
GCA SEC Phase IV study Tocilizumab Cipla rare disease

Related News